Home World News Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with...

Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma

September 21, 2026

153

Findings from the final 5-year analysis of overall survival in the IMCgp100-202 study